Staphylococcus cohnii Is a Potentially Biotherapeutic Skin Commensal Alleviating Skin Inflammation

Scientists found that Tmem79−/− mice spontaneously develop interleukin-17-producing T-cell-driven skin inflammation. Comparative skin microbiome analysis revealed that the disease activity index is negatively associated with S. cohnii.
[Cell Reports]
Ito, Y., Sasaki, T., Li, Y., Tanoue, T., Sugiura, Y., Skelly, A. N., Suda, W., Kawashima, Y., Okahashi, N., Watanabe, E., Horikawa, H., Shiohama, A., Kurokawa, R., Kawakami, E., Iseki, H., Kawasaki, H., Iwakura, Y., Shiota, A., Yu, L., … Honda, K. (2021). Staphylococcus cohnii is a potentially biotherapeutic skin commensal alleviating skin inflammation. Cell Reports, 35(4). https://doi.org/10.1016/j.celrep.2021.109052 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Autoreactive T Cells and Their Role in Atopic Dermatitis

The authors evaluate the development of (autoreactive) T cells and their response to (auto)antigens, as well as the role of the peripheral tolerance in autoimmunity in the pathophysiology of atopic dermatitis (AD), including the unmet needs and gaps.
[Journal of Autoimmunity]
Autoreactive T cells and their role in atopic dermatitis. (2021). Journal of Autoimmunity, 120, 102634. https://doi.org/10.1016/j.jaut.2021.102634 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Nuclear IL-33 Plays an Important Role in the Suppression of Filaggrin, Loricrin, Keratin 1, and Keratin 10 by IL-4 and IL-13 in Human Keratinocytes

Researchers investigated whether intracellular IL-33 is involved in IL-4/IL-13 function. In monolayer-culture and living skin equivalent, IL-4/IL-13 increased the expression of full-length IL-33 in the nucleus of keratinocytes by activating the MEK/ERK signaling pathway, which is necessary for the inhibition of differentiation markers filaggrin, loricrin, keratin1, and keratin 10.
[Journal of Investigative Dermatology]
Dai, X., Utsunomiya, R., Shiraishi, K., Mori, H., Muto, J., Murakami, M., & Sayama, K. (2021). Nuclear IL-33 plays an important role in the suppression of filaggrin, loricrin, keratin 1, and keratin 10 by IL-4 and IL-13 in human keratinocytes. Journal of Investigative Dermatology, 0(0). https://doi.org/10.1016/j.jid.2021.04.002 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Eczema Herpeticum in Atopic Dermatitis

Scientists give an overview of the clinical picture, and characteristics of the patients as well as the diagnosis and therapy of eczema herpeticum.
[Allergy]
Abstract
Bookmark

No account yet? Register

0
Share

Does the Epithelial Barrier Hypothesis Explain the Increase in Allergy, Autoimmunity and Other Chronic Conditions?

Scientists discuss how the immune responses to dysbiotic microbiota that cross the damaged barrier may be involved in the development of allergic and autoimmune diseases.
[Nature Reviews Immunology]
Akdis, C. A. (2021). Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nature Reviews Immunology, 1–13. https://doi.org/10.1038/s41577-021-00538-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie announced that the US FDA has extended the review period for the supplemental New Drug Application for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
[AbbVie (PRNewswire)]
Press Release
Bookmark

No account yet? Register

0
Share

Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis

Pfizer, Inc. announced that the US FDA has extended the priority review period for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe atopic dermatitis.
[Pfizer Inc. (businesswire)]
Press Release
Bookmark

No account yet? Register

0
Share

Development of a Human Skin Commensal Microbe for Bacteriotherapy of Atopic Dermatitis and Use in a Phase I Randomized Clinical Trial

The authors investigated the safety and mechanisms of action of Staphylococcus hominis A9, a bacterium isolated from healthy human skin, as a topical therapy for atopic dermatitis.
[Nature Medicine]
Nakatsuji, T., Hata, T. R., Tong, Y., Cheng, J. Y., Shafiq, F., Butcher, A. M., Salem, S. S., Brinton, S. L., Rudman Spergel, A. K., Johnson, K., Jepson, B., Calatroni, A., David, G., Ramirez-Gama, M., Taylor, P., Leung, D. Y. M., & Gallo, R. L. (2021). Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nature Medicine, 1–10. https://doi.org/10.1038/s41591-021-01256-2 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Understanding the Key Issues in the Treatment of Uncontrolled Persistent Asthma with Type 2 Inflammation

Researchers summarize the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.
[European Respiratory Journal]
Busse, W. W., Kraft, M., Rabe, K. F., Deniz, Y., Rowe, P., Ruddy, M., & Castro, M. (2021). Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. European Respiratory Journal. https://doi.org/10.1183/13993003.03393-2020 Cite
Abstract
Bookmark

No account yet? Register

0
Share

BELLUS Health Announces First Patient Dosed in its Phase II BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis

BELLUS Health Inc. announced that the first patient has been dosed in the Phase II BLUEPRINT trial of BLU-5937, the company’s highly selective P2X3 antagonist, in patients with chronic pruritus associated with atopic dermatitis.
[BELLUS Health Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

RINVOQ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) for Primary and All Ranked Secondary Endpoints in Phase IIIb Head-to-Head Study in Adults with Atopic Dermatitis

AbbVie announced top-line results from the Phase IIIb Heads Up study showing that upadacitinib achieved superiority to dupilumab for the primary endpoint, the proportion of patients with at least a 75% improvement in the Eczema Area Severity Index at week 16, in adults with moderate to severe atopic dermatitis.
[AbbVie (PR Newswire, LLC)]
Press Release
Bookmark

No account yet? Register

0
Share
Share